Prostate cryoablation is an established minimally invasive treatment for localized prostate cancer (PCa). However, the impairment of erectile function (EF) is considered a serious complication of the procedure. To investigate the efficacy of erectile aids following cryotherapy, 93 patients who underwent whole gland prostate cryoablation with required complete medical records were analyzed. The changes in postoperative EF were evaluated using the International Index of Erectile Function (IIEF-5) questionnaire. Additionally, independent factors that could have a correlation to the postoperative IIEF-5 score or postoperative Expanded Prostate Cancer Index Composite (EPIC) score were assessed. In the entire cohort, the mean preoperative IIEF-5 score was 7.0 ± 6.2. A total of 72 (77.4%) patients had moderate-to-severe preoperative erectile dysfunction. In longitudinal investigation, the patients using erectile aids showed the ability to recover to baseline after 24 months from cryoablation compared with the patients not using erectile aids. There were significant differences of IIEF-5 scores between these groups at 24 months (7.5 vs 3.0; P ¼ 0.025) and 36 months (8.5 vs 3.5; P ¼ 0.010). In multivariate analysis, the use of erectile aids correlated with restoration of IIEF-5 scores (odds ratio, 5.11; confidence interval (CI), 1.87-13.96; Po0.001) and lower EPIC sexual bother (coef, 19.61; CI,; P ¼ 0.046). Our data indicate that on-demand use of erectile aids could help restore EF and reduce sexual bother after whole gland prostate cryoablation. Although, erectile aids could not play a role as an adequate treatment for ED after whole gland prostate cryoablation, these results may aid in the decision-making process for PCa patients with preoperative and postoperative ED who have concern about sexual health-related quality of life.
Introduction
In the 1960s, the first report of prostate cryoablation was published by Gonder et al.;
1 however, the imprecision and immature technology resulted in unsatisfactory oncological outcome and morbidity. Presently, third-generation cryoablation using argonhelium gas, 17-gauge cryoneedles and real-time ultrasound-guided imaging has significantly improved both oncological and morbidity outcomes after surgery. [2] [3] [4] To date, cryoablation is recognized as an established minimally invasive procedure for localized prostate cancer (PCa) in both the primary and salvage setting. [3] [4] [5] The importance of health-related quality of life (HRQoL) in men after treatment for PCa has been emphasized in accordance with the need for improvement in the management of PCa. In this context, erectile dysfunction potentially has a great impact on a patient's HRQoL after definitive treatment for PCa. 6, 7 Currently, the assessment of sexual function after cryoablation is needed for the purpose of providing both the clinician and patient with information about sexual recovery. Although several reports detailing oncological outcomes of cryoablation have been published, there are few series reporting postoperative HRQoL (for example urinary function or sexual function) using validated HRQoL instrument assessments after prostate cryoablation. In addition, predictive factors that can affect erectile function (EF) after prostate cryoablation are still unknown.
In this study, the 5-item International Index of Erectile Function (IIEF-5) and Expanded Prostate Cancer Index Composite (EPIC) were used as validated questionnaires. We evaluated preoperative IIEF-5 and postoperative IIEF-5/EPIC scores to assess EF longitudinally based upon several perspectives. Additionally, multivariate analyses were conducted to determine independent predictive factors associated with restoration of postoperative EF following prostate cryoablation.
Materials and methods

Patients
After approval from the Institutional Review Board, records of patients treated from 2002 to 2008 were retrieved from our prospectively maintained cryosurgical database. Before cryosurgery, all patients had biopsy-proven PCa and were staged according to the 2002 American Joint Committee on Cancer classification staging system. All patients underwent whole gland prostate cryoablation at the Duke University Medical Center. Excluded criteria were patients who used erectile aids before cryosurgery or those who were subjected to postoperative androgen deprivation therapy (ADT). We also excluded patients who were not in a stable relationship or who were not heterosexual. An informed consent was obtained from all patients before treatment.
Instruments EF was evaluated using both the IIEF-5 and the EPIC questionnaire. IIEF-15 is a validated instrument consisting of 15 questions developed in patients with ED that resulted from multiple etiologies. 8 The IIEF-5 is a short version of the IIEF-15 that potentially demonstrates the ability to assess the prevalence and severity of ED. 9 The EPIC questionnaire is also a validated instrument specific to HRQoL in men with PCa, developed by PCa researchers. 10 The EPIC consists of four domains including urinary, bowel, sexual and hormonal. We calculated a sexual domain, sexual function and a sexual bother score. These scores range from 0 to 100, with higher scores representing better HRQoL.
Cryoablation procedure
The procedure was performed by a single surgeon (TJP). All the patients were treated with thirdgeneration cryotechnology using 17-gauge cryoneedles (Galil Medical, Arden Hills, MN, USA). For the cryoablation procedure, the patient was placed in a lithotomy position under general anesthesia and a Foley catheter was placed. Using transrectal ultrasound guidance, the cryoprobes were sequentially placed through a brachy template into the prostate by standard protocol. Appropriate needle positioning was verified by ultrasound image in both the sagittal and the transverse dimensions; a thermocouple was placed at the level of the urinary sphincter as well as in Denonvillier's fascia. Cystoscopy was performed to ensure the cryotherapy needles did not violate the urethra, and a urethral warming catheter was subsequently placed to maintain a temperature of B42 1C during the procedure. The urinary sphincter was maintained at temperatures 40 1C, and freezing was stopped when the iceball reached the anterior rectal wall and the posterior prostatic capsule measured at least À20 1C. A dual freeze-thaw cycle was used. Following the final passive thaw, the urethral warming catheter remained in situ an additional 20 min. All cryoprobes were then removed and a Foley catheter was placed. The patient was discharged and a voiding test was performed within 1-2 weeks.
Data collection
For an objective assessment of EF, the IIEF-5 was obtained preoperatively and postoperatively at 3, 6, 12, 18, 24 and 36 months after surgery. A preoperative IIEF-5 score was obtained at a clinic visit immediately before surgery. Additionally, a postoperative EPIC score was collected in 54 patients. The restoration of EF was defined as that when the total IIEF-5 score was the same or changed to a higher score at the last follow-up time point compared with the preoperative score. 
Results
Baseline characteristics
According to our criteria, a total of 93 consecutive patients were enrolled in this study. Baseline characteristics of this cohort and comparison between primary and salvage cryoablation are summarized in Table 1 . Preoperative IIEF-5 scores are detailed in Table 2 . In this cohort, 66 (71.0%) patients underwent primary prostate cryoablation and 27 (29.0%) patients underwent salvage prostate cryoablation following external-beam radiotherapy or brachytherapy. A total of 18 (19.4%) patients were subjected to temporal preoperative ADT for downsizing of the prostate gland, which was discontinued before cryosurgery. The mean surgical age and follow-up period was 67.7 ± 7.4 years and 50.1±20.1 months, respectively. Of the 93 patients, 33 (35.1%) patients used erectile aids after surgery. Among the 33 patients, the erectile aids included PDE5 inhibitors in 24 patients, transurethral prostaglandin in 3 patients, intracavernous injections in 3 patients and a vacuum erection device in 3 patients. There was no significant difference between primary and salvage patients except for age (P ¼ 0.003), prostate volume (Po0.001) and body mass index (P ¼ 0.002).
Changes in EF after cryoablation in the entire cohort Longitudinal changes in the mean IIEF-5 scores of the cohort at pretreatment, 3, 6, 12, 18, 24 and 36 months are illustrated in Figure 1 . The mean IIEF-5 score was minimally worsened at 3 months after surgery, which was statistically different compared with that of baseline (Po0.001). However, the score started to recover from 18 months, with no statistical difference in the IIEF-5 score by 24 months (7.0 vs 4.1; P ¼ 0.392). Although the IIEF-5 score showed a trend toward recovery, the score did not reach the same level compared with the score at baseline by 36 months after ablation (7.0 vs 5.8; P ¼ 0.943).
Changes in EF after cryoablation based upon subcategories
The changes in IIEF-5 scores based upon use of erectile aids are detailed in Figure 2 . The patients using erectile aids showed the ability to restore their IIEF-5 score after cryoablation compared with patients not using erectile aids. When comparing changes from baseline to the last observation period longitudinally, the mean IIEF-5 score of erectile aid users increased from 7.2 to 8.5 (P ¼ 0.041), whereas the mean score of non-users decreased from 6.9 to 3.5 (Po0.001). Moreover, erectile aid users showed significantly higher mean IIEF-5 scores compared with that of non-users at 24 months (7.5 vs 3.0; P ¼ 0.025) and 36 months (8.5 vs 3.5; P ¼ 0.010), while the mean IIEF-5 score at baseline, 3, 6, 12 and
18 months did not demonstrate statistical differences between those groups. The changes in IIEF-5 scores based upon operation type (primary vs salvage) were also analyzed. Both patient groups had a trend to develop worsen IIEF-5 scores immediately after ablation and then recovered gradually after 12-18 months. No differences were found between these groups during the entire observation period.
Multivariate analysis to predict factors for restoration of IIEF-5 scores Table 3 reports a logistic regression analysis for predicting factors associated with restoring postoperative IIEF-5 scores to its preoperative score after cryoablation. Of the 93 patients, 35 (37.6%) patients could restore their IIEF-5 scores at 36 months after surgery. In the multivariate analysis, use of erectile aids was found as the only significant independent factor to predict restoration of postoperative IIEF-5 scores after surgery (odds ratio, 5.11; confidence interval (CI), 1.87-13.96; Po0.001). Depression demonstrated a high negative correlation with maintenance of IIEF-5 scores after surgery; however, Operation type represents primary cryoablation vs salvage cryoablaton. The restoration of erectile function was defined as that when the total IIEF-5 score was the same or changed to a higher score at the last follow-up time point compared with the preoperative score.
Use of erectile aids following prostate cryoablation M Kimura et al it did not show a significant difference (odds ratio, 0.45; CI, 0.09-2.05; P ¼ 0.303). Table 4 summarizes the logistic regression analysis for predicting factors associated with higher postoperative EPIC sexual domain scores after cryoablation. A total of 54 patients who had postoperative EPIC scores were included in this analysis. In this setting, the median EPIC score was 29.8. For conducting logistic regression analysis, the cut point of postoperative EPIC score was assigned as 430 based on the median EPIC score of this cohort. Again, this analysis revealed that the use of erectile aids was the only independent factor that correlated with better outcomes of sexual function following surgery (odds ratio, 5.13; CI, 1.22-21.37; P ¼ 0.025). Table 5 represents a multivariate linear regression analysis regarding the correlation between either EPIC sexual function or sexual bother against several variables. This analysis demonstrated that the use of erectile aids had a significant positive correlation with the sexual bother score (coef, 19.61; CI, 0.32-38.89; P ¼ 0.046), suggesting that use of erectile aids was associated with lower sexual bother after cryosurgery. Additionally, age at surgery was also found to be an independent factor that had a positive correlation with the sexual bother score (coef, 2.29; CI, 0.88-3.20; P ¼ 0.002), indicating that older men had lower sexual bother. In this cohort, the mean EPIC sexual function score and sexual bother score were 12.0±16.2 and 59.2±33.3, respectively.
Discussion
In the present study, 37.6% of patients could restore their IIEF-5 scores by 36 months after surgery, although the majority of patients had moderate or severe preoperative ED. Based upon a meta-analysis study, recovery rate of EF after prostate cryoablation is lower than that of several other localized treatment options. The reported probability of maintaining EF were 60% for brachytherapy plus external-beam radiotherapy, 52% for external-beam radiotherapy, 25% for nerve-sparing prostatectomy and 15% for cryotherapy. 11 In terms of EF after cryoablation, there are only a few articles reporting longitudinal changes using either direct interview 12, 13 or validated instruments. [14] [15] [16] Those reports describe that 39.0-51.3% of patients recover EF with penile rehabilitation or using erectile aids. Although prostate cryoablation has been reported to impair EF, likely resulting from freezing bilateral cavernous nerves close to the apex, one explanation for those men recovering EF may be due to nerve regeneration after freeze damage mentioned by several investigators in animal and human studies. 14, 17 The main finding of our study is that the ondemand use of erectile aids was identified as the only independent predictive factor to restore postoperative IIEF-5 scores by multivariate analysis. The effect of PDE5 inhibitors have been unclear in the prostate cryoablation setting to date, since most series reported full treatment such as routine penile rehabilitation, 2, 12, 16 as well as lacking information about use of erectile aids, 2,13 which resulted in no information to compare between erectile aid users and non-users. In our study, erectile aids can clearly restore postoperative IIEF-5 scores to that of the preoperative score by the end of the observation period. The mechanism and role of erectile aids has been described in several articles. [18] [19] [20] [21] [22] In an animal model, use of a PDE5 inhibitor preserved smooth muscle content and endothelial function in penile tissue, and maintained nerve structures. 20 Therefore, we anticipate that even though cryoablation may potentiate bilateral cavernous nerve damage, PDE5 inhibitors can protect against further tissue Use of erectile aids following prostate cryoablation M Kimura et al damage following ablation and might enhance nerve regeneration. Albeit taking into account the benefits of erectile aids for both EF and sexual bother, most of our cohort who had preoperative mild ED or normal EF had impaired EF after surgery. Similarly, patients who could restore their EF to baseline by using erectile aids still suffer from severe ED postoperatively. Thus, the critical insult to EF still exists even if using erectile aids after whole gland prostate cryoablation. In other words, erectile aids could not provide an adequate treatment for ED after whole gland prostate cryoablation. Therefore, we need an alternative means to preserve the cavernous nerves, such as focal ablation or a nerve protector that could be an ideal approach for the patient who desires minimal sexual morbidity in the prostate cryosurgery setting. Our results suggest that salvage cryoablation did not have any correlation with postoperative EF. In contrast, our previous study demonstrated that the salvage setting was an independent factor to worsened urinary function after cryoablation. 23 Anastasiadis et al. 24 reported on 131 consecutive patients who underwent primary and salvage cryoablation. In this study, urinary function worsened in the salvage setting compared with primary cryoablation, yet EF was not significantly different between the groups, consistent with our studies. We expect that EF (for example the cavernous nerves) is more sensitive to cryo-induced complications than that of urinary function in both the primary and salvage setting.
Depression was identified as a factor that had a strong negative correlation with IIEF-5 scores (odds ratio, 0.45; CI, 0.09-2.05; P ¼ 0.303) among several preoperative variables. This might be related to the sideeffects of antidepressants such as serotonin reuptake inhibitors that were typically administrated to patients categorized as 'depressed' in our cohort. However, one randomized study demonstrated that sildenafil effectively improved IIEF-5 scores in men with ED associated with the use of serotonin reuptake inhibitors. 25 This finding supports our data, suggesting that even if patients took antidepressants, the use of erectile aids could help restore their IIEF-5 score after cryosurgery. Several articles also reported that ADT can negatively affect sexual function including EF and libido. [26] [27] [28] However, our study excluded the patients who use postoperative ADT. Additionally, in multivariate analysis, we could not find any relationship between preoperative ADT exposure and postoperative EF scores. Therefore, we believe temporary preoperative ADT might not affect postoperative EF in the current study.
The present study is not void of limitations. First, the population of this cohort consists of men who tend to be older than other series and the majority of men had severe preoperative ED. According to radical prostatectomy series, the mean age ranged from 61.7 to 63.5 years and the proportion of severe preoperative ED ranged from 28 to 32%. [29] [30] [31] Because prostate cryoablation was not considered as a treatment option for patients who desired to preserve their EF after surgery in this series, there may have been patient selection bias. Second, this is a retrospective report involving a single center that may be subject to inherent biases compared with a randomized, blinded study. In fact, use of erectile aids was based upon a patient's will/demand. Therefore, the patients who used erectile aids may be more determined to preserve their EF. Third, our cohort is relatively small (n ¼ 93) and represents a heterogeneous population including both primary and salvage patients partially subjected to preoperative ADT that might introduce a bias even though these were not found as variables affecting postoperative EF. Finally, we did not adjust the current analyses by overall amount of preoperative comorbidities as these were not fully known. Therefore, potential undisclosed biases could affect the results of multivariate analyses.
Despite those limitations, the current study provides information about the utility of erectile aids after whole gland prostate cryoablation, especially among men with moderate and severe preoperative ED. To our knowledge, this is the first report using validated instruments and multivariate analyses, revealing that erectile aid users were more likely to restore their IIEF-5 score and experience less sexual bother, even if the entire prostate gland was ablated. Given that many patients, especially who had preoperative normal EF or mild ED, are suffering from severe postoperative ED, a more robust and aggressive strategy should be considered for preserving postoperative EF. Thus, the implications of this study were (1) cryoablation must be as focused as possible, (2) using EF aids could be of major importance for recovering posttreatment EF and (3) still there is no adequate approach for healing from either preoperative or postoperative ED.
Conclusions
Whole gland cryoablation that may cause cavernous nerve damage was previously believed to have a negative impact on EF after surgery. However, this study implies that on-demand use of erectile aids could be a contributing factor to the restoration of postoperative EF and reduction of sexual bother after prostate cryosurgery for patients with preoperative moderate and severe ED. Although erectile aids may not play a role as an adequate treatment for men with preoperatively normal EF or preoperatively mild ED after whole gland prostate cryoablation, this study may be beneficial in the decisionmaking process and stimulate aggressive use of erectile aids for preoperative and postoperative ED patients who have concern about sexual HRQoL following prostate cryoablation.
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